Navigation Links
Montclair Breast Center introduces 3D Mammography.

Montclair, NJ (PRWEB) May 02, 2013

Montclair Breast Center is one of the first women’s centers in New Jersey to offer 3D mammography (breast tomosynthesis) for breast cancer screening. Breast tomosynthesis produces a three-dimensional view of the breast tissue that helps radiologists identify and characterize individual breast structures without the confusion of overlapping tissue.

The center’s Selenia® Dimensions® breast tomosynthesis system is made by Hologic, a world leader in digital mammography. The Selenia Dimensions system offers exceptionally sharp breast images, an advanced ergonomic design providing more patient comfort, and the ground-breaking tomosynthesis platform designed to deliver superior screening and diagnostic performance.

Breast tomosynthesis will benefit all screening and diagnostic mammography patients, and is especially valuable for women receiving a baseline screening, those who have dense breast tissue and/or women with a personal history of breast cancer.

Breast cancer screening with tomosynthesis when combined with a conventional 2D mammography has a higher cancer detection rate than conventional 2D mammography alone.{1} Tomosynthesis technology gives radiologists increased confidence with a significant reduction in recall rates. {2}

The tomosynthesis screening experience is similar to a traditional mammogram. During a tomosynthesis exam, multiple, low-dose images of the breast are acquired at different angles. These images are then used to produce a series of one-millimeter thick slices that can be viewed as a 3D reconstruction of the breast.

Breast cancer is the second leading cause of cancer death among women, exceeded only by lung cancer. Statistics indicate that one in eight women will develop breast cancer sometime in her lifetime. The stage at which breast cancer is detected influences a woman’s chance of survival. If detected early, the five-year survival rate is 98 percent. {3}

Of patients who began and continued their screening at Montclair Breast Center and were diagnosed with breast cancer in 2012, 95% were diagnosed at the most treatable Stages 0 or 1. The national average for such early diagnosis in all women is just 60%. This extremely high rate of early detection reflects Montclair Breast Center’s breast imaging expertise, physician/patient collaboration, and attention to detail.

In offering breast tomosynthesis digital mammography, Montclair Breast Center provides the latest in imaging technology. If you would like to schedule a 3D mammogram or have questions about this important breast health procedure, please visit Montclair Breast Center, or call 973-509-1818.

About Montclair Breast Center: Montclair Breast Center is a premier, multidisciplinary breast center, specializing in proactive breast healthcare, risk-reduction techniques and the early detection and treatment of breast cancer. Our nationally recognized, dedicated team of breast imagers and breast surgeons use the most sophisticated technologies and are committed to providing better breast care than anywhere.

{1} Skaane P, Gullien R, Eben EB, et. al. Reading time of FFDM and tomosynthesis in a population-based screening program. Radiological Society of North America annual meeting. Chicago, Il, 2011.
{2} Hologic, Inc. FDA PMA submission P080003.
{3} Breast Cancer Facts & Figures 2011, American Cancer Society.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Stereotactic Breast Biopsy introduced with Fischer-Giotto Image at American Society of Breast Surgeons course
2. Robert Lowen MD, Expert Bay Area Plastic Surgeon, Announces Cutting-Edge 3-D Crisalix Imaging Technology to Aid Patients in Choosing their Breast Implant Size
3. Patti Flint MD, A Top Female Plastic Surgeon in the Southwest, Is Proud To Offer Cutting-Edge 3D Crisalix Technology to Patients When Selecting Breast Implants
4. Dr. Vasquez at the Connecticut Plastic Surgery Group Now Offers the Unique Crisalix 3D Simulations for Facial Aesthetics and Breast Augmentation
5. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
6. The First Dedicated Breast Cancer Cell Line Transfection Reagent
7. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
8. University of Maryland Breast Cancer Research Pioneer Dr. Angela Brodie Appointed Fellow of New American Association for Cancer Research Academy
9. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
10. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
11. Frost & Sullivan: Modest Growth Projected in the U.S. Breast Imaging Systems Market Amidst Increasing Breast Cancer Prevalence
Post Your Comments:
(Date:12/1/2015)... DUBLIN , December 1, 2015 /PRNewswire/ ... the addition of the  "2016 U.K. Virology ... Segment Forecasts for 100 Tests, Supplier Shares ... Opportunities"  report to their offering.  --> ... of the  "2016 U.K. Virology and Bacteriology ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced that ... closed system for isolating adipose-derived stem cells. The announcement starts a new phase toward ... SVF is a component of the lipoaspirate obtained from liposuction of excess adipose tissue. ...
(Date:11/30/2015)... ... ... Cells Group announced the opening of a new core patient care hub with the ... The facilities are part of GSCG’s expansion efforts in Latin America. , Both the ... to patients from around the world. , The clinics will be headed by Victor Perez, ...
(Date:11/30/2015)... Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... joined the American Business Act on Climate Pledge, alongside more ... standing with the Obama Administration to demonstrate an ongoing commitment ... outcome to the COP21 Paris climate ... Sarnia, Canada . --> BioAmber ...
Breaking Biology Technology:
(Date:11/30/2015)... DEERFIELD BEACH, Fla. , Nov. 30, 2015 ... selected as a finalist in this year,s Fierce Innovation ... publisher of FierceHealthIT , ... BIOCLAIM was recognized as a finalist in the ... --> ...
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
Breaking Biology News(10 mins):